業績・論文 2016

*脳脊髄腫瘍科

1.Ishizawa K, Tsukamoto Y, Ikeda S, Suzuki T, Homma T, Mishima K, Nishikawa R, Sasaki A.  ‘Papillary’ solitary fibrous tumor/hemangiopericytoma with nuclear STAT6 expression and NAB2-STAT6 fusion.  Brain Tumor Pathology 33:151-156, 2016.

2.Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, Shishido-Hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, Nishikawa R, Nagane M, Mano H.  Genomic characterization of primary central nervous system lymphoma.  Acta Neuropathol 131:865-875, 2016

3.Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R.  Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma:  comprehends safety results during and after first-line therapy.  Neuro Oncol 18:991-1001, 2016.

4.Ichimura K, Fukushima S, Totoki Y, Matsushima Y, Otsuka A, Tomiyama A, Niwa T, Takami H, Nakamura T, Suzuki T, Fukuoka K, Yanagisawa T, Mishima K, Nakazato Y, Hosoda F, Narita Y, Shibui S, Yoshida A, Mukasa A, Saito N, Kumabe T, Kanamori M, Tominaga T,
5.Kobayashi K, Shimizu S, Nagane M, Iuchi T, Mizoguchi M, Yoshimoto K, Tamura K, Madehara T, Sugiyama K, Nakada M, Sakai K, Kanemura Y, Nonaka M, Asai A, Yokogami K, Takeshima H, Kaawahara N, Takayama T, Yao M, Kato M, Nakamura H, Hama N, Sakai R, Ushijima T, Matsutani M, Shibata T, Nishikawa R, Intracranial Germ Cell Tumor Genome Analysis Consortium.  Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. Acta Neuropathol 131:889-901, 2016

6.Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C , Abrey L, Wick W.  Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy:  an exploratory analysis of AVAglio.  Neuro Oncol 18:1313-1318, 2016

7.Fukuoka K, Yanagisawa T, Suzuki T, shirahata M, Adachi J, Mishima K, Fujimaki T, Katakami H, Matsutani M, Nishikawa R.  Human chorionic gonadotropin detection in cerebrospinal fluid of patients with a germinoma and its prognostic significance:  assessment by using a highly sensitive enzyme immunoassay.  J Neurosurg Pediatr 18:573-577, 2016

8.Huang T, Alvarez AA, Pangeni RP, M Horbinski C, Lu S, Kim SH, James CD, J Raizer J, A Kessler J, Brenann CW, Sulman EP, Finocchiaro G, Tan M, Nishikawa R, Lu X, Nakano I, Hu B, Chang SY.  A regulatory circuit of miR-125b/miR-20b and Wnt signaling controls glioblastoma phenotypes through FZD6-modulated pathways.  Nat Commun, 2016 Oct 4;7:12885.

 
9.Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Jujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara

10.N, Ueki Kn Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K.  A combination of TERT promotor mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.  Acta Neuropathol Commun 4:79-, 2016.

11.Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T.  Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.  Neuro Oncol 18:1434-1441, 2016

Sano H, Deguchi I, Fukuoka T, Hayashi T, Uchino A, Adachi J, Yasuda M, Takao M, Tanahashi N.  Intractable neurosarcoidosis effectively treated with Infliximab.  Internal Medicine 55:811-814, 2016.

12.三島一彦: 悪性グリオーマに対する放射線増感による新規治療法の開発 埼玉医科大学雑誌 43(1): 28-32, 2016

13.三島一彦: 脳腫瘍治療ガイドライン・脳腫瘍取扱い規約 中枢神経系原発悪性リンパ腫. 脳腫瘍学 日本臨床 74: 320-335, 2016

14.三島一彦: 脳腫瘍の分子標的治療 抗EGFR抗体による悪性グリオーマの治療. 脳腫瘍学 日本臨床 74: 677-688, 2016

 
ページの先頭へ トップページへ